Study Protocol

Study Protocol

NCT02555878 Janssen Scientific Affairs* Clinical Protocol Efficacy and Safety of Rivaroxaban Prophylaxis Compared with Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism Protocol BAY59-7939/39039039STM4001/18262 Phase 3b AMENDMENT-4 JNJ39039039/BAY59-7939 (Rivaroxaban) * Rivaroxaban (BAY-59-7939, JNJ-39039039) is being co-developed under collaboration and license agreement between Bayer HealthCare AG (BHC) and Ortho McNeil Pharmaceuticals, Inc. (OMP) dated October 1, 2005. As determined by the parties, both BHC and Janssen Pharmaceuticals Inc. (successor in interest to OMP) may use affiliated corporate entities to conduct this clinical trial. With regard to Janssen Pharmaceuticals Inc., such affiliates may include Janssen Research & Development, LLC (formerly Johnson & Johnson Pharmaceutical Research & Development LLC), Janssen Scientific Affairs, LLC, and Janssen-Cilag International NV. The term "sponsor" or "designee" is used throughout the protocol to represent these various legal entities that have been identified to perform various clinical trial services; the actual sponsor or designee is identified on the Contact Information page that accompanies this protocol. This study will be conducted under US Food & Drug Administration IND regulations (21 CFR Part 312). EudraCT NUMBER: 2015-001630-21 Status: Approved Date: 16 February 2018 Prepared by: Janssen Scientific Affairs, LLC EDMS number: EDMS-ERI-102610148: 6.0 GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory requirements. Confidentiality Statement The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or confidential. 1 Status: Approved, Date: 16 February 2018 NCT02555878 JNJ39039039/BAY59-7939 (Rivaroxaban) Clinical Protocol BAY59-7939/39039039STM4001/18262 Amendment-4 TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................................... 2 LIST OF ATTACHMENTS............................................................................................................................ 4 LIST OF IN-TEXT FIGURES ........................................................................................................................ 4 PROTOCOL AMENDMENTS....................................................................................................................... 5 SYNOPSIS.................................................................................................................................................. 21 TIME AND EVENTS SCHEDULE .............................................................................................................. 31 ABBREVIATIONS ...................................................................................................................................... 33 1. INTRODUCTION................................................................................................................................ 35 1.1. Background .................................................................................................................................... 35 1.2. Overall Rationale for the Study ...................................................................................................... 37 2. OBJECTIVES AND HYPOTHESIS ................................................................................................... 39 2.1. Objectives ...................................................................................................................................... 39 2.2. Hypothesis ..................................................................................................................................... 40 3. STUDY DESIGN AND RATIONALE ................................................................................................. 40 3.1. Overview of Study Design.............................................................................................................. 40 3.2. Study Design Rationale.................................................................................................................. 44 4. SUBJECT POPULATION.................................................................................................................. 48 4.1. Inclusion Criteria ............................................................................................................................ 48 4.2. Exclusion Criteria ........................................................................................................................... 50 4.3. Prohibitions and Restrictions ......................................................................................................... 52 5. TREATMENT ALLOCATION AND BLINDING................................................................................. 53 6. DOSAGE AND ADMINISTRATION .................................................................................................. 54 7. TREATMENT COMPLIANCE............................................................................................................ 55 8. PRESTUDY AND CONCOMITANT THERAPY ................................................................................ 55 9. STUDY EVALUATIONS .................................................................................................................... 58 9.1. Study Procedures........................................................................................................................... 58 9.1.1. Overview..................................................................................................................................... 58 9.1.2. Screening Phase ........................................................................................................................ 58 9.1.3. Double-Blind Treatment Phase .................................................................................................. 59 9.1.4. Post-treatment Phase (Follow Up) (Day 181 – Day 210) ........................................................... 61 9.2. Efficacy Evaluations and Outcomes .............................................................................................. 62 9.2.1. Efficacy Evaluations and Outcomes........................................................................................... 62 9.2.1.1. Definitions ................................................................................................................................ 64 9.2.2. Efficacy Endpoints ...................................................................................................................... 65 9.2.3. Approach to the Subject with an Efficacy Outcome Event ......................................................... 66 9.3. Safety Evaluations ......................................................................................................................... 66 9.3.1. Bleeding Events.......................................................................................................................... 66 9.3.1.1. Management of Study Drug for Bleeding Events .................................................................... 67 9.3.2. Other Safety Assessments ......................................................................................................... 68 9.3.2.1. Adverse Events ....................................................................................................................... 68 9.3.2.2. Clinical Laboratory Tests ......................................................................................................... 68 9.3.2.3. Vital Signs................................................................................................................................ 69 2 Approved, Date: 16 February 2018 NCT02555878 JNJ39039039/BAY59-7939 (Rivaroxaban) Clinical Protocol BAY59-7939/39039039STM4001/18262 Amendment-4 9.3.2.4. Medical History and Physical Examination.............................................................................. 69 9.4. Biomarkers ..................................................................................................................................... 70 9.4.1. Evaluations ................................................................................................................................. 70 9.5. Pharmacokinetics........................................................................................................................... 70 9.5.1. Pharmacokinetic Sample Collection and Handling..................................................................... 70 9.5.2. Analytical Procedures ................................................................................................................. 70 9.5.3. Pharmacokinetic Parameters ..................................................................................................... 70 9.6. Health Care Resource Utilization..................................................................................................

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    112 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us